display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - NA - PDL1 positive
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone KEYNOTE 054 ...

Study type: